Praxis Precision Medicines, Inc. (PRAX): who owns it and who trades it
As of Nov 16, 2026, PRAX insiders reported 18 open-market sales worth $11.1M and no purchases in the last 12 months, with 33% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alex Nemiroff (General Counsel and Secr), with $4.9M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Praxis Precision Medicines
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Famous investors and Congress mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, PRAX insiders reported $0 of open-market purchases and $11.1M of sales. 33% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 10 | $301.44 | $3K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 1,279 | $314.90 | $403K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 837 | $315.71 | $264K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 504 | $313.66 | $158K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 1,004 | $312.83 | $314K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 2,854 | $311.91 | $890K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 1,750 | $310.89 | $544K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 999 | $309.38 | $309K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 1,240 | $308.24 | $382K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 683 | $306.77 | $210K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 320 | $305.31 | $97.7K | Form 4 |
| Jun 24, 2026 | Jill DeSimone | Director | Sale plan | 120 | $303.13 | $36.4K | Form 4 |
| Nov 20, 2025 | Alex Nemiroff | General Counsel and Secr | Sale | 9,100 | $194.30 | $1.8M | Form 4 |
| Nov 20, 2025 | Alex Nemiroff | General Counsel and Secr | Sale | 977 | $193.23 | $189K | Form 4 |
| Nov 20, 2025 | Alex Nemiroff | General Counsel and Secr | Sale | 13,339 | $192.53 | $2.6M | Form 4 |
| Nov 20, 2025 | Alex Nemiroff | General Counsel and Secr | Sale | 1,714 | $190.86 | $327K | Form 4 |
| Nov 20, 2025 | Lauren Mastrocola | Principal Accounting Off | Sale | 2,145 | $192.71 | $413K | Form 4 |
| Nov 20, 2025 | Lauren Mastrocola | Principal Accounting Off | Sale | 11,455 | $191.96 | $2.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alex Nemiroff | General Counsel and Secretary | – | $4.9M | Nov 20, 2025 |
| Jill DeSimone | Director | – | $3.6M | Jun 24, 2026 |
| Lauren Mastrocola | Principal Accounting Officer | – | $2.6M | Nov 20, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PRAX short interest
High short interest. 15.1% of PRAX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.21M PRAX shares were sold short, 15.1% of the shares outstanding, up 7.3% from the report before. At the average daily volume of 484,385 shares, buying them all back would take about 8.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.21M | 15.07% | +7% | 484,385 | 8.7 |
| Oct 15, 2026 | 3.92M | 14.05% | -6% | 529,120 | 7.4 |
| Sep 30, 2026 | 4.19M | 15.00% | +10% | 585,284 | 7.2 |
| Sep 15, 2026 | 3.80M | 13.59% | +1% | 255,094 | 14.9 |
| Aug 31, 2026 | 3.74M | 13.40% | +1% | 368,146 | 10.2 |
| Aug 14, 2026 | 3.71M | 13.30% | +2% | 476,576 | 7.8 |
| Jul 31, 2026 | 3.66M | 13.10% | -3% | 322,416 | 11.3 |
| Jul 15, 2026 | 3.76M | 13.50% | -6% | 408,462 | 9.2 |
| Jun 30, 2026 | 3.99M | 14.30% | +12% | 773,350 | 5.2 |
| Jun 15, 2026 | 3.57M | 12.80% | -2% | 649,949 | 5.5 |
| May 29, 2026 | 3.65M | 13.10% | -2% | 302,516 | 12.1 |
| May 15, 2026 | 3.71M | 13.30% | -2% | 402,661 | 9.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded PRAX
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of PRAX. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.
Purchases 2Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 12, 2026 | Report |
| Jul 30, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 4, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Praxis Precision Medicines company events
Praxis Precision Medicines filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 7, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the Company entered into a research collaboration and license agreement with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems, to develop an iontophoretic transdermal patch for the delivery of… Filing
- Jul 2, 2026AuditorThe Audit Committee of the Board of Directors of Praxis Precision Medicines, Inc. approved the dismissal of Ernst & Young LLP as the Company's independent registered public accounting firm, effective as of that date. Filing
- Jun 29, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration notified the Company that it has extended by three months the review period for its New Drug Application for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies, setting… Filing
- Jun 22, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of… Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AnnouncementPraxis Precision Medicines, Inc. announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 14, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults. Filing
- Apr 6, 2026AnnouncementPraxis Precision Medicines, Inc. is providing the following business updates: Elsunersen The Company announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A development and epileptic encephalopathy. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Feb 10, 2026LeadershipAmended an earlier report. Praxis Precision Medicines, Inc. filed a Current Report on Form 8-K disclosing that the Board of Directors of the Company elected Jeffrey B. Kindler and Stuart A. Arbuckle to the Board, each as a Class II director, effective January 8, 2026. Filing
- Jan 8, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Jan 7, 2026AnnouncementPraxis Precision Medicines, Inc. entered into an underwriting agreement with Piper Sandler & Co., TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule A thereto, relating to an underwritten offering of 2,212,000 shares of the… Filing
- Jan 6, 2026ResultsReleased financial results. Filing
- Dec 29, 2025AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for ulixacaltamide for the treatment of patients with essential tremor. Filing
- Dec 11, 2025AnnouncementPraxis Precision Medicines, Inc. announced the completion of a Type C meeting with the U.S. Food and Drug Administration and agreement to immediately convert the EMBRAVE3 registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy into a single-arm study where… Filing
- Dec 8, 2025AnnouncementPraxis Precision Medicines, Inc. announced the successful completion of its pre-New Drug Application meeting with the U.S. Food and Drug Administration, including receipt of written feedback and an in-person meeting. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Praxis Precision Medicines financials
Famous investors that hold PRAX
2 of the 50 well-known investors we track reported holding PRAX in their latest 13F filing. The largest position is Ken Griffin's, worth $6.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 21,080 | $6.1M | 0.0% | +188% |
| Israel Englander · Millennium Management | Q3 2026 | 7,339 | $2.1M | 0.0% | +638% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PRAX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ORBIS INVESTMENT MANAGEMENT LTD | 13G/A | 4.9% |
| Nov 16, 2026 | ORBIS INVESTMENT MANAGEMENT LTD | 13G/A | 4.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.2% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.2% |
Questions about Praxis Precision Medicines, Inc. (PRAX) stock
Are PRAX insiders buying or selling?
In the last 12 months, PRAX insiders reported no open-market purchases and 18 sales worth $11.1M. The latest trade was on Jun 24, 2026. See every trade.
What is the short interest in PRAX?
As of Oct 30, 2026, 4.21M PRAX shares were sold short, 15.1% of the shares outstanding, up 7.3% from the report before. At the average daily volume of 484,385 shares, buying them all back would take about 8.7 trading days (days to cover). See the history.
Have members of Congress traded PRAX?
Yes. 1 member of Congress reported 2 purchases and 0 sales of PRAX since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold PRAX?
2 of the 50 well-known investors we track reported PRAX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $6.1M. See all holders.
Executive pay
Praxis Precision Medicines's chief executive was paid a total of $8.7M for the year ended Dec 31, 2025, down 35% from $13.4M the year before. In the last 12 months, Praxis Precision Medicines's executives and directors bought no stock on the open market and sold $11.1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.